MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

73.69 +0.15 (+0.20%)
Streaming Delayed Price Updated: 12:47 PM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder ↗
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS. 
Via Benzinga
News headline image
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another ↗
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes. 
Via Benzinga
News headline image
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
From Biogen Inc.
Via GlobeNewswire
News headline image
The 3 Most Undervalued Pharma Stocks to Buy in May 2024 ↗
Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks. 
Via InvestorPlace
News headline image
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For Ionis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals ↗
 
Via Benzinga
News headline image
IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ↗
IONS stock results show that Ionis Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows ↗
Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with... 
Via Benzinga
News headline image
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
News headline image
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
From Biogen Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 21, 2024 ↗
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
News headline image
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts ↗
 
Via Benzinga
News headline image
JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines ↗
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval. 
Via Benzinga
News headline image
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study ↗
Phase 3 OASIS-HAE study results by Ionis Pharmaceuticals Donidalorsen shows remarkable efficacy, safety, and plans for FDA submission. 
Via Benzinga
News headline image
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
News headline image
Where Ionis Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs ↗
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,... 
Via Benzinga
Topics ETFs
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies ↗
These future trillion dollar stocks can solidify portfolio growth for long-term investors. Discover the stocks to buy in 2024. 
Via InvestorPlace
News headline image
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am 
Via Benzinga
News headline image
Analyst Expectations for Ionis Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment ↗
Friday, FDA approved AstraZeneca 
Via Benzinga
News headline image
Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach ↗
Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,... 
Via Benzinga
News headline image
Based on good technical signals, IONIS PHARMACEUTICALS INC is potentially setting up for a breakout. ↗
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Reveals Intriguing Technical Aspects. Here's What You Need to Know. 
Via Chartmill
News headline image
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Technical Insights for IONIS PHARMACEUTICALS INC (NASDAQ:IONS): Is a Breakout Imminent? ↗
Technical Setup: IONIS PHARMACEUTICALS INC Appears Poised for a Breakout. 
Via Chartmill
News headline image
Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story